Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genexol-PM + Carboplatin in Gynecologic Cancer
NCT02739529Phase 1Unknown
- Sponsor
- Samyang Biopharmaceuticals Corporation
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paclitaxel polymeric micelle in gynecologic cancer (3 cohorts), sponsored by Samyang Biopharmaceuticals Corporation. Primary endpoints: Maximum Tolerated Dose at 2 years and Recommended Phase II Dose at 2 years. Status: unknown.
02
Drugs
paclitaxel polymeric micelle
03
Conditions
gynecologic cancer
Beyond the preview
Go deeper on NCT02739529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739529.